ANI Pharmaceuticals (NASDAQ: BPAX) and Concert Pharmaceuticals (NASDAQ:CNCE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
Institutional & Insider Ownership
62.0% of Concert Pharmaceuticals shares are owned by institutional investors. 15.3% of Concert Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares ANI Pharmaceuticals and Concert Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
| Concert Pharmaceuticals | $82,000.00 | 3,945.32 | -$49.11 million | ($2.23) | -6.39 |
ANI Pharmaceuticals has higher revenue, but lower earnings than Concert Pharmaceuticals.
Analyst Ratings
This is a summary of current recommendations and price targets for ANI Pharmaceuticals and Concert Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| Concert Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
Concert Pharmaceuticals has a consensus target price of $26.40, suggesting a potential upside of 85.13%. Given Concert Pharmaceuticals’ higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than ANI Pharmaceuticals.
Profitability
This table compares ANI Pharmaceuticals and Concert Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 5.99% | 6.12% | 3.00% |
| Concert Pharmaceuticals | -60,681.70% | -61.98% | -48.50% |
Summary
Concert Pharmaceuticals beats ANI Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company’s product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
Receive News & Ratings for ANI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
